Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
Sveva Di Franco
Antibiotics
View PDFchevron_right
Meta-analysis of Clinical Outcomes Using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections
Charlesnika Evans
Open Forum Infectious Diseases, 2021
View PDFchevron_right
Ceftolozane/tazobactam: place in therapy
Paolo Grossi
Expert review of anti-infective therapy, 2018
View PDFchevron_right
Real-world evaluation of ceftolozane/tazobactam therapy and clinical outcomes in France
R. Ruimy
Infectious Diseases Now, 2021
View PDFchevron_right
In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study
Elmano Ramalheira
International Journal of Antimicrobial Agents, 2020
View PDFchevron_right
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
Alex Soriano
Infectious Diseases and Therapy, 2021
View PDFchevron_right
Ceftolozane/Tazobactam Versus Colistin in the Treatment of Ventilator-Associated Pneumonia Due to Extensively Drug-Resistant Pseudomonas Aeruginosa: A Comparative Cohort Study
Zsolt Iványi
2021
View PDFchevron_right
A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections
Joao Massud
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2002
View PDFchevron_right
Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP
Julie Passarell
Antimicrobial Agents and Chemotherapy
View PDFchevron_right
Activity of Ceftolozane-Tazobactam Tested against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States During 2013 to 2015
Diego Llampa Mendoza
Antimicrobial agents and chemotherapy, 2017
View PDFchevron_right
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
Tiziana Tieghi
Clinical Infectious Diseases, 2020
View PDFchevron_right
Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections
Jose Arbelo Hidalgo
Drug Design, Development and Therapy, 2016
View PDFchevron_right
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
Tiziana Tieghi
International Journal of Antimicrobial Agents, 2018
View PDFchevron_right
Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam/ß-lactamase inhibitor combination
Ashwini Tayade
Journal of Microbiology and Infectious Diseases, 2012
View PDFchevron_right
A Phase 3 Randomized Double-blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime plus Linezolid for the Treatment of Hospital-acquired Pneumonia
Samir Awad
Clinical Infectious Diseases, 2014
View PDFchevron_right
Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
Alberto Maraolo
Open Forum Infectious Diseases, 2020
View PDFchevron_right
Comparative Clinical Evaluation of Safety and Effiacy of Cefotaxime and Ceftriaxone in Lower Respiratory Tract Infections
IOSR Journals
View PDFchevron_right
Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa
Zsolt Iványi
Scientific Reports, 2022
View PDFchevron_right
In-vitro activity of ceftolozane/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals
wail tashkandi
Journal of Infection and Public Health, 2022
View PDFchevron_right
Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa
Kerry Cleveland
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015
View PDFchevron_right
Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
Samer Mouksassi
Journal of clinical pharmacology, 2015
View PDFchevron_right
Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: A multicenter study
Deepali Dixit
Open Forum Infectious Diseases
View PDFchevron_right
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
Helio Sader
Journal of Antimicrobial Chemotherapy, 2014
View PDFchevron_right
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
Ronald Jones
Antimicrobial Agents and Chemotherapy, 2013
View PDFchevron_right
1581. Comparative In Vitro Activity of Ceftolozane/tazobactam and Comparator Agents Against Enterobacteriaceae and Pseudomonas Aeruginosa Clinical Isolates in Colombia
Cristhian Hernández-Gómez
Open Forum Infectious Diseases, 2019
View PDFchevron_right
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
Johan Mouton
Journal of Antimicrobial Chemotherapy, 2013
View PDFchevron_right
Are third-generation cephalosporins unavoidable for empirical therapy of community-acquired pneumonia in adult patients who require ICU admission? A retrospective study
Arnaud Galbois
View PDFchevron_right
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-Abdominal Infections, Complicated Urinary Tract Infections and Nosocomial Pneumonia
Wright W Nichols
Antimicrobial Agents and Chemotherapy
View PDFchevron_right